Examining Opioid Treatment Infrastructure Act of 2021

Bill: 117-hr-1686
Sponsor: full_name: Rep. Foster, Bill [D-IL-11]
Introduced: 2021-03-09
Policy area: Health
Subjects: Alaska Natives and Hawaiians

Child health

Congressional oversight

Drug therapy

Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Government studies and investigations

Health information and medical records

Home and outpatient care

Hospital care

Indian social and development programs

Minority health

Women's health
Latest action: action_date: 2021-05-07
text: Referred to the Subcommittee for Indigenous Peoples of the United States.

Summaries:
action_date: 2021-03-09
action_desc: Introduced in House
text: <p><b>Examining Opioid Treatment Infrastructure Act of </b><b>2021</b></p> <p>This bill requires the Government Accountability Office to report on the availability of and unmet need for substance use disorder treatment and recovery services, including for specified populations. The report must also address barriers to real-time reporting of drug overdoses at the federal, state, and local levels.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 1686 IN THE HOUSE OF REPRESENTATIVES March 9, 2021 Mr. Foster introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Natural Resources , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To direct the Comptroller General of the United States to evaluate and report on the inpatient and outpatient treatment capacity, availability, and needs of the United States.

1. Short title This Act may be cited as the Examining Opioid Treatment Infrastructure Act of 2021 . 2. Study on treatment infrastructure Not later than 24 months after the date of enactment of this Act, the Comptroller General of the United States shall initiate an evaluation of, and submit to Congress a report on, the inpatient and outpatient treatment capacity, availability, and needs of the United States, including, to the extent data are available— (1) the capacity of acute residential or inpatient detoxification programs; (2) the capacity of inpatient clinical stabilization programs, transitional residential support services, and residential rehabilitation programs; (3) the capacity of demographic specific residential or inpatient treatment programs, such as those designed for pregnant women or adolescents; (4) geographical differences of the availability of residential and outpatient treatment and recovery options for substance use disorders across the continuum of care; (5) the availability of residential and outpatient treatment programs that offer treatment options based on reliable scientific evidence of efficacy for the treatment of substance use disorders, including the use of Food and Drug Administration-approved medicines and evidence-based nonpharmacological therapies; (6) the number of patients in residential and specialty outpatient treatment services for substance use disorders; (7) an assessment of the need for residential and outpatient treatment for substance use disorders across the continuum of care; (8) the availability of residential and outpatient treatment programs to American Indians and Alaska Natives through an Indian health program (as defined by section 4 of the Indian Health Care Improvement Act ( 25 U.S.C. 1603 )); and (9) the barriers (including technological barriers) at the Federal, State, and local levels to real-time reporting of de-identified information on drug overdoses and ways to overcome such barriers.